Featured Research

from universities, journals, and other organizations

Value Of Direct-to-consumer Drug Advertising Oversold, Study Finds

Date:
September 3, 2008
Source:
Harvard Medical School
Summary:
In the first-ever controlled study measuring the effectiveness of pharmaceutical direct-to-consumer advertising, researchers found only a modest effect on drug sales. In some cases, DTCA had no effect at all.

Direct-to-consumer advertising may not be giving big pharma such a big bang for their buck after all. Despite the billions spent on bringing drug marketing campaigns straight into patients' living rooms, such strategies have a modest effect at best—and in some cases, no effect at all.

"People tend to think that if direct-to-consumer advertising wasn't effective, pharma wouldn't be doing it," says Harvard Medical School professor Stephen Soumerai, principal investigator on the study. "But as it turns out, decisions to market directly to consumers is based on scant data."

This study was based at the Department of Ambulatory Care and Prevention of Harvard Medical School and Harvard Pilgrim Health Care and appears September 2 online in the British Medical Journal. It is the first-ever controlled study of direct-to-consumer advertising (DTCA) of pharmaceuticals.

Currently, the United States and New Zealand are the only countries that allow drug companies to advertise directly to patients. When the U.S. Food and Drug Administration eased advertising restrictions on the pharmaceutical industry in 1997, consumer advertising jumped 330 percent over the next 10 years. As of 2005, pharma was spending about $5 billion annually on such campaigns. Some data implied that such ads increased prescriptions, but these studies simply correlated ads with sales, begging the question, are drugs that sell more simply advertised more?

But examining the effects of advertising on sales via a controlled study is problematic. Given the overwhelming amount of advertising in the U.S., how do you find two groups that are very similar, yet one is exposed to pharmaceutical advertising and the other isn't?

The answer: Canada.

DTCA is illegal in Canada. Not surprisingly, however, national borders are leaky and American media—television and magazines and radio, replete with pharma ads—regularly crosses into Canada. As a result, Canadians, like Americans, are swamped with these ads, with one key exception.

All American advertisements are in English. Yet Canada has a significant French-speaking population. In the Canadian province of Quebec, approximately 80 percent of its 7.5 million population speak French as their first language, and tend to get most of their news from French-language media. As a result, residents of Quebec, on the whole, are far less exposed to DTCA than other Canadians.

Quebec, then, functioned as a control group for the study. The researchers compared prescription rates for advertised drugs in English-speaking Canadian provinces with rates in Quebec, where residents were purportedly less exposed to those same ads.

"It's not an absolutely perfect control group," says Michael Law, first author on the paper. "There's obviously a small percentage of Quebec residents who are exposed to English language media. But as control groups go for this sort of observational study, it's about as good as you get."

Law and Soumerai chose to look at three specific drugs: Enbrel (rheumatoid arthritis), Nasonex (nasal allergies), and Zelnorm (irritable bowel sydrome). All three drugs were on the market for at least one year before the DTCA campaign began, and none were advertised in Canada through "softer" consumer ads, that is, ads that may mention the drug by name without identifying the relevant conditions.

The basic question was simple: did use of these drugs increase faster in English-speaking regions after American DTCA campaigns began?

Using information from IMS Health Canada, a health information company that receives data from a panel of about 2,700 Canadian pharmacies, the researchers analyzed prescription statistics for each of these three drugs for a five-year period.

They found that for two of the drugs, Enbrel and Nasonex, DTCA had no effect whatsoever. Prescription patterns in English-speaking Canada and in Quebec remained identical both before and after DTCA campaigns began.

Sales for Zelnorm, however, did spike noticeably in English-speaking Canada as soon as the ad campaign began. While prescriptions for this drug increased by over 40 percent, this jump was relatively short-lived, and after a few years, prescription rates in both groups resumed identical patterns. A similar analysis of U.S. Medicaid prescriptions found a slightly higher, but similarly brief, jump in sales.

The researchers hypothesize that DTCA may not be as effective as other types of consumer advertising due to the unique complexity of the marketing/sales trajectory.

With a typical consumer product, an individual sees an ad and then can choose to simply go out and buy the item. "But pharmaceuticals aren't typical consumer products," says Soumerai. "A person needs to see an ad, get motivated by that ad, contact their doctor for an appointment, show up at the appointment, communicate both the condition and the drug to the doctor, convince the doctor that this drug is preferable to other alternatives, then actually go out and fill the prescription. This is a chain of events that can break at any point."

This hypothesis may in fact explain the disparate effects of DTCA on these three drugs. For Enbrel and Nasonex, there are a number of over-the-counter and prescription alternatives that doctors would likely recommend as first-line treatments.

Zelnorm, however, was the only drug on the market in both the United States and Canada for constipation-predominant irritable bowel syndrome. The researchers suggest that Zelnorm would have sold very well without the consumer advertising.

In March of 2007, Zelnorm was pulled from the market due to FDA concerns that it may increase risk for heart attack and stroke.

One hundred years of marketing experience and recent studies indicate that face-to-face promotion of drugs to doctors by pharmaceutical representatives is far more effective than DTCA.

This research was supported by Harvard Medical School and Harvard Pilgrim Health Care, The Social Sciences and Humanities Research Council of Canada, The Alberta Heritage Foundation for Medical Research, and the Agency for Healthcare Research and Quality.

The funding and data sources for this study had no role in study design; in the collection, analysis, and interpretation of data; or in the writing of the report.

Funding sources were Harvard Medical School and Harvard Pilgrim Health Care, The Social Sciences and Humanities Research Council of Canada, The Alberta Heritage Foundation for Medical Research and Agency for Healthcare Research and Quality.


Story Source:

The above story is based on materials provided by Harvard Medical School. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael Law et al. Effect of illicit direct-to-consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. British Medical Journal, September 2, 2008

Cite This Page:

Harvard Medical School. "Value Of Direct-to-consumer Drug Advertising Oversold, Study Finds." ScienceDaily. ScienceDaily, 3 September 2008. <www.sciencedaily.com/releases/2008/09/080901205629.htm>.
Harvard Medical School. (2008, September 3). Value Of Direct-to-consumer Drug Advertising Oversold, Study Finds. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/09/080901205629.htm
Harvard Medical School. "Value Of Direct-to-consumer Drug Advertising Oversold, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2008/09/080901205629.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Cases Keep Coming for Monrovia's Island Hospital

Ebola Cases Keep Coming for Monrovia's Island Hospital

AFP (Oct. 1, 2014) A look inside Monrovia's Island Hospital, a key treatment centre in the fight against Ebola in Liberia's capital city. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Ebola Puts Stress on Liberian Health Workers

Ebola Puts Stress on Liberian Health Workers

AP (Oct. 1, 2014) The Ebola outbreak is putting stress on first responders in Liberia. Ambulance drivers say they are struggling with chronic shortages of safety equipment and patients who don't want to go to the hospital. (Oct. 1) Video provided by AP
Powered by NewsLook.com
Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Newsy (Sep. 30, 2014) After the announcement that the first U.S. patient had been diagnosed with Ebola, doctors were quick to say a U.S. outbreak is highly unlikely. Video provided by Newsy
Powered by NewsLook.com
TX Hospital Confirms Patient Admitted With Ebola

TX Hospital Confirms Patient Admitted With Ebola

AP (Sep. 30, 2014) Medical officials from Texas Health Presbyterian Hospital confirm they are treating a patient with the Ebola virus, the first case found in the US. (Sept. 30 Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins